Core Viewpoint - Zejing Pharmaceutical has entered into a global development and commercialization strategic cooperation and licensing option agreement with AbbVie for ZG006, which includes significant upfront and milestone payments, indicating strong potential for revenue growth and market expansion in oncology treatments [1][3]. Group 1: ZG006 Collaboration with AbbVie - The agreement grants AbbVie exclusive rights to develop and commercialize ZG006 outside Greater China, while Zejing retains rights within the region [3]. - Zejing has received an upfront payment of $100 million and may receive up to $60 million in milestone payments, with potential additional milestone payments of up to $1.075 billion if the licensing option is exercised [3]. - The collaboration is expected to enhance Zejing's innovation profile and international influence, providing more treatment options for global patients [3]. Group 2: Clinical Data and Progress of ZG006 - ZG006 is currently in clinical trials for small cell lung cancer and neuroendocrine cancer, showing promising efficacy and safety [4]. - In a Phase II trial for late-stage small cell lung cancer, ZG006 demonstrated an overall response rate (ORR) of 53.3% and a median progression-free survival (mPFS) of 7.03 months [4]. - In neuroendocrine cancer patients, the ORR was 38.5%, with a notable 66.7% in DLL3-positive patients [4]. Group 3: ZG005 Clinical Data and Development - ZG005 is advancing in clinical trials for liver cancer, neuroendocrine cancer, and cervical cancer, with a confirmed ORR of 40.9% and disease control rate (DCR) of 68.2% in cervical cancer patients [5]. - The drug has shown encouraging activity in early studies for advanced cervical cancer and liver cancer, indicating broad potential for combination therapies [5]. Group 4: Sales and Market Strategies - The injection of human thyroid-stimulating hormone β (Zesuning®) has been approved for post-surgical diagnosis in differentiated thyroid cancer, marking it as the first innovative product in this area in China [6]. - Zejing has partnered with Merck for exclusive promotion of Zesuning®, aiming to enhance its market presence in personalized diagnosis for thyroid cancer patients [6]. - The company’s Jikaxitini tablets have been included in the national medical insurance directory, expected to positively impact sales due to its classification as a first-line treatment in clinical guidelines [7]. Group 5: Financial Performance Forecast for 2025 - Zejing anticipates revenue between 796.49 million and 828.99 million yuan for 2025, representing a year-on-year increase of 49.45% to 55.55% [9]. - The revenue growth is primarily driven by the inclusion of recombinant thrombin in the national medical insurance directory and the commercialization of Jikaxitini [9]. - Despite the revenue increase, the company expects to report a net loss due to rising sales and research expenses [9].

Core Viewpoint - Company announced a collaboration with WuXi AppTec to enhance its drug development capabilities and reduce clinical trial time and costs [1] Group 1 - Company’s subsidiary, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., signed a technical service contract with WuXi AppTec [1] - The collaboration is expected to expand the company's drug research and development capacity [1] - The agreement aims to ensure the smooth progress of projects by saving time and costs associated with clinical trials [1]

Core Viewpoint - Fosun Pharma has signed a licensing agreement with Expedition for the global development, production, and commercialization of the investigational product XH-S004, excluding mainland China and Hong Kong and Macau [1] Group 1: Licensing Agreement Details - The agreement allows Expedition to develop and commercialize XH-S004 globally, while Fosun Pharma retains rights for development and commercialization in mainland China and Hong Kong and Macau [1] - Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments related to development and regulatory achievements [1] - Additionally, Expedition may pay up to $525 million in sales milestone payments based on annual net sales performance of the licensed product in the licensed regions [1] Group 2: Product Information - XH-S004 is a small molecule oral DPP-1 inhibitor developed by Fosun Pharma, aimed at reducing inflammation and blocking the cycle of infection and airway structural damage [1] - Potential indications for XH-S004 include non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease [1] Group 3: Strategic Implications - This collaboration is expected to accelerate the clinical development and commercialization of the licensed product globally [1] - The partnership will also help expand Fosun Pharma's innovative product portfolio in international markets [1]

Group 1 - The company held its 15th meeting of the 10th board of directors on May 30, 2025, with all 9 directors participating, complying with relevant laws and regulations [1] - The company plans to hold the 2024 annual shareholders' meeting on June 20, 2025, with all votes in favor [1] - The board approved amendments to the "Performance Bonus Incentive Measures" to optimize the incentive mechanism and enhance overall operational efficiency [2] Group 2 - The company’s wholly-owned subsidiary, Harbin Pharmaceutical Group Bioengineering Co., Ltd., signed a technology transfer contract with Shanghai Bozhi Research New Drug Co., Ltd., with a total contract value of 44.8 million yuan [2] - The contract includes clear terms regarding technical objectives, payment methods, and liability for breach of contract, acknowledging the uncertainties involved in drug development [3] - The company will adhere to information disclosure obligations as per the Shanghai Stock Exchange regulations [3]